Osu03012 是一种口服生物可利用的小分子塞来昔布衍生的磷酸肌醇依赖性激酶 1 (PDK1) 抑制剂，具有潜在的抗肿瘤活性。

AR-12 is an orally bioavailable, small-molecule, celecoxib-derived inhibitor of phosphoinositide-dependent kinase-1 (PDK1) with potential antineoplastic activity.

在MDA-MB-435 / LCC6异种移植物模型中,OSU-03012显着降低肿瘤中EGFR蛋白的表达,同时还阻止YB-1与的EGFR启动子结合.在Huh7 移植瘤中,OSU-03012（200 mg/kg）能够抑制肿瘤细胞生长.在HMS-97神经鞘瘤异种移植物模型中,口服给药OSU-03012能够抑制细胞生长.

OSU-03012浓度为3-5 μM时即可完全抑制多种肿瘤细胞生长。在甲状腺癌细胞(NPA, WRO和ARO细胞)中,OSU-03012作为ATP竞争性抑制剂,通过 抑制PAK活性和AKT磷酸化,从而抑制细胞增殖和迁移,诱导细胞凋亡。在肝细胞癌细胞系（Huh7, Hep3B和HepG2细胞）中,OSU-03012（IC50<1 μM）抑制细胞生长。其中,对于Huh7细胞,OSU-03012诱导细胞发生自噬。在神经胶质瘤细胞、PC-3细胞中,OSU-03012能够促进细胞凋亡。

PDK-1 Kinase Assay: This in vitro assay is performed using a PDK-1 kinase assay kit. This cell-free assay is based on the ability of recombinant PDK-1, in the presence of DMSO vehicle or OSU-03012, to activate its downstream serum- and glucocorticoid-regulated kinase which, in turn, phosphorylates the Akt/serum- and glucocorticoid-regulated kinase-specific peptide substrate RPRAATF with [γ-32P]ATP. The 32P-phosphorylated peptide substrate is then separated from the residual [γ-32P]-ATP by using P81 phosphocellulose paper and quantitated in a scintillation counter after three washes with 0.75% phosphoric acid.

The effect of OSU-03012 on PC-3 cell viability is assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay in six replicates. Cells are grown in 10% FBS- supplemented RPMI 1640 in 96-well, flat-bottomed plates for 24 hours. They are exposed to various concentrations of OSU-03012 (0-10 μM) dissolved in DMSO (final concentration ≤0.1%) in 1% serum-containing RPMI 1640 for different time intervals (~72 hours). Controls receive DMSO vehicle at a concentration equal to that in OSU-03012-treated cells. The medium is removed and replaced by 200 μL of 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in 10% FBS-containing RPMI 1640. The cells are incubated in the CO2 incubator at 37 °C for 2 hours. Supernatants are removed from the wells, and the reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye is solubilized in 200 μL DMSO per well. Absorbance at 570 nm is determined by using a plate reader.(Only for Reference)

742112-33-0

C26H19F3N4O

460.46

AR-12;Osu-03012;Osu 03012

Ethanol:<1 mgml
H2O:<1 mgml
DMSO:9 mg/mL (19.5 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years